1. Standardizing Ways to Create New Treatments for Under-served Disease Markets, with Stem Cell Technology
Can stem cell technology be used to make under-served disease markets commercially relevant? Professor Marc Peschanski is working with stem cells (embryonic and adult) to create therapeutics for monogenic diseases. His goal and that of his institute are to standardize new ways of creating treatments for monogenic diseases, developing R&D with an emphasis on the technology platform.
2. Is Europe attractive for stem cell research? Which countries are the most advanced and have the most favorable legislation?
Professor Marc Peschanski discusses the different european legislations, looking at the countries that have taken the lead, and those quickly progressing – including the U.K., Germany, and Spain. He then continues to explain changes in French law that are making stem cell research possible.
3. Stem Cell Research Financing, Products, Business Models, and Regulatory Concerns
Why is stem cell financing limited, and how does I-Stem finance its research? Professor Marc Peschanski looks at the capital question, and potential applications of stem cell research. He then reviews the concerns of the regulators and compares the FDA and EMEA with respect to stem cells.
4. Will Adult Stem Cells Resolve Our Moral Quandaries? Do They Offer The Same Benefits As Embryonic Stem Cells?
Is the public opinion antagonistic towards, divided on, or supportive of stem cells? Professor Marc Peschanski explains the state of the debate, now that stem cells can be derived from adult tissue. He also comments on the applicability of human embryonic stem cell technology towards adult stem cell technology.
This interview was conducted at the NASDAQ Marketsite, on June 10th, 2008, in New York City.
Featuring:
DISCLAIMER: VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.